- KEI’s Initial Comments on the MPP/BMS license to patents and know-how for daclatasvir (DCV)
- 23 November 2015: Opening statement of Asia and the Pacific Group at Tenth Session of WIPO Advisory Committee on Enforcement
- US ITC notice for public comment, Jan 13, 2016 hearing, and Commission report on the TransPacific Partnership Agreement (TPP)
- My testimony this morning at the US ITC hearing on "Economic Impact of Trade Agreements"
- Seminars on Drug Pricing: Part 5 Kevin Outterson, Antibiotic Delinkage
- Tentative witness list for USITC hearing on Economic Impact of Trade Agreements
- Dr. Margaret Chan: TPP may "close access to affordable medicines"
- US Chamber of Commerce lauds USPTO for securing a time-bound LDC waiver for pharmaceutical products
- Economist Bhaven Sampat presents research on role of government funding in drug development
- Joint NGO Statement on TRIPS Council Decision On Extension of the Transition Period Concerning Pharmaceutical Products
Development Agenda committee mandates WIPO to examine Bolivia, Barbados, Suriname and Bangladesh prize proposalsSubmitted by thiru on 13. December 2010 - 7:14
On Friday, 26 November 2010, the 6th session of the WIPO Committee on Development Agenda and Intellectual Property approved a project entitled "Project on Open Collaborative Projects and IP-Based Models". As mentioned in KEI's previous posting on this subject, this project endeavors to implement Recommendation 36 of the Development Agenda which states:
13 December 2010
Drug Name(s) HERCEPTIN (Brand Name Drug)
FDA Application No. (BLA) 103792
Active Ingredient(s) TRASTUZUMAB
Company GENENTECH (Roche acquired a majority ownership in 1990, and full ownership in March 2009.)
Original Approval or Tentative Approval Date September 25, 1998
What is Herceptin? How does it work?
For background on the Fabrazyme case, see: http://www.keionline.org/fabrazyme
The following statements were made today by civil society on the NIH rejection of the Fabrazyme March-in Request Petition. Contact Judit Rius at firstname.lastname@example.org if your organization would like to submit an statement.
Statement by James Love, Director of Knowledge Ecology International (KEI) (Contact: 1.202.361.3040)
CDIP6: Bolivia's intervention on WIPO's proposed project on 'Open Collaborative Projects and IP-Based Models'Submitted by thiru on 25. November 2010 - 5:51
25 November 2010
The fourth day of WIPO's Committee on Development and Intellectual Property(CDIP6) has witnessed a rich discussion on how to implement Recommendation 36 of the WIPO Development Agenda which states:
Recommendation 36 (Cluster D): To exchange experiences on open collaborative projects such as the Human Genome Project as well as on intellectual property models
KEI statement to Committee on Development and Intellectual Property on WIPO project on IP and Competition PolicySubmitted by thiru on 24. November 2010 - 9:43
Knowledge Ecology International made the following intervention today at the 6th Session of the WIPO Committee on Development and Intellectual Property (CDIP).
KEI statement to WIPO CDIP 6 on Agenda item 5
Thank you Ambassador and congratulations on your appointment as Chair of this Committee.
Revealing study by L Yager (GAO): 'Observations on efforts to quantify the economic effects of counterfeit and pirated goods'Submitted by thiru on 24. November 2010 - 6:01
The 6th session of the WIPO Advisory Committee on Enforcement is taking place in Geneva from 1-2 December 2010. KEI's observations on the 5th session, entitled, Positive outcome reached at WIPO Advisory Committee on Enforcement while ACTA looms in the East can be found here:http://keionline.org/node/681.
On November 19, 2010, Knowledge Ecology International, Medecins Sans Frontieres/Doctors without Borders, Oxfam America and Public Citizen answered a Request for Comments from the US Department of Commerce on a proposal to "Incentivize Humanitarian Technologies and Licensing Through the Intellectual Property System".
Today I am attending a meeting at the European Parliament on new models of innovation for medical technologies. The event was organized by three MEPs, Thijs Berman, Eva Joly and Carl Schlyter, in collaboration with the European Parliament Working Group on Innovation, Access to Medicines and Poverity-Related Diseaes, and several consumer rights, public health and development NGOs (TACD, Health Action International, KEI, Oxfam and IQsensato).
Non-responsive letter from David Kappos of USPTO to Senators Sanders and Brown regarding ACTA consistency with US lawSubmitted by James Love on 17. November 2010 - 12:56
In a October 19, 2010, Senators Bernard Sanders (I-VT) and Sherrod Brown (D-OH) wrote to David Kappos, the Director of the USPTO, asking for an assessment of conflicts between the October 2010 ACTA text, and U.S. law. (attached here).
|Undersecretary of Commerce for
Intellectual Property, David Kappos
From: James Love
To: Michele Woods
Cc: Nancy Weiss
Subject: Some examples of US inconsistency with ACTA
Date: Fri, 12 Nov 2010 07:29:09 -0500
This note cites several areas where US law is plainly inconsistent with
In addition, in a separate analysis,I have called attention to proposed
legislation in USA on orphan copyrighted works that are very
inconsistent with ACTA provisions on remedies.
Some examples of inconsistencies between ACTA and US law
Sometime very early Saturday morning, SCCR 21 ended with these conclusions.
Communication to SCCR delegates regarding the beneficiaries of a new WIPO treaty for copyright exceptions for disabilitiesSubmitted by thiru on 12. November 2010 - 11:03
12 November 2010
The delegates to the SCCR are considering various proposals to deal with expanded access to copyrighted works by persons who are blind or who have other disabilities.
The proposal sponsored by Brazil, Ecuador, Mexico and Paraguay would extend the benefits of the treaty, not only to persons who are blind or visually impaired, but also as follows: